These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 27252040)

  • 1. The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.
    Zinzani PL; Rigacci L; Cox MC; Devizzi L; Fabbri A; Zaja F; Di Rocco A; Rossi G; Storti S; Fattori PP; Argnani L; Vitolo U
    Leuk Lymphoma; 2017 Jan; 58(1):226-229. PubMed ID: 27252040
    [No Abstract]   [Full Text] [Related]  

  • 2. Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.
    Zinzani PL; Rigacci L; Cox MC; Devizzi L; Fabbri A; Zaccaria A; Zaja F; Di Rocco A; Rossi G; Storti S; Fattori PP; Argnani L; Tura S; Vitolo U
    Leuk Lymphoma; 2015 Jun; 56(6):1671-6. PubMed ID: 25241999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapy.
    Rosenthal A; Dueck AC; Ansell S; Gano K; Conley C; Nowakowski GS; Camoriano J; Leis JF; Mikhael JR; Keith Stewart A; Inwards D; Dingli D; Kumar S; Noel P; Gertz M; Porrata L; Russell S; Colgan J; Fonseca R; Habermann TM; Kapoor P; Buadi F; Leung N; Tiedemann R; Witzig TE; Reeder C
    Am J Hematol; 2017 May; 92(5):467-472. PubMed ID: 28230270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete remission following lenalidomide and rituximab in a patient with heavily pretreated nodular lymphocyte predominant Hodgkin lymphoma.
    Cheah CY; Mistry HE; Konoplev S; Fowler NH
    Leuk Lymphoma; 2016 Aug; 57(8):1974-6. PubMed ID: 26762971
    [No Abstract]   [Full Text] [Related]  

  • 5. The evolving role of lenalidomide in non-Hodgkin lymphoma.
    Galanina N; Petrich A; Nabhan C
    Leuk Lymphoma; 2016 Jul; 57(7):1507-16. PubMed ID: 26902680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.
    Kritharis A; Coyle M; Sharma J; Evens AM
    Blood; 2015 Apr; 125(16):2471-6. PubMed ID: 25736312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
    Sacchi S; Marcheselli R; Bari A; Buda G; Molinari AL; Baldini L; Vallisa D; Cesaretti M; Musto P; Ronconi S; Specchia G; Silvestris F; Guardigni L; Ferrari A; Chiapella A; Carella AM; Santoro A; Di Raimondo F; Marcheselli L; Pozzi S
    Haematologica; 2016 May; 101(5):e196-9. PubMed ID: 26858355
    [No Abstract]   [Full Text] [Related]  

  • 8. Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
    Tuscano JM; Dutia M; Chee K; Brunson A; Reed-Pease C; Abedi M; Welborn J; O'Donnell RT
    Br J Haematol; 2014 May; 165(3):375-81. PubMed ID: 24606326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
    Fowler NH; Davis RE; Rawal S; Nastoupil L; Hagemeister FB; McLaughlin P; Kwak LW; Romaguera JE; Fanale MA; Fayad LE; Westin JR; Shah J; Orlowski RZ; Wang M; Turturro F; Oki Y; Claret LC; Feng L; Baladandayuthapani V; Muzzafar T; Tsai KY; Samaniego F; Neelapu SS
    Lancet Oncol; 2014 Nov; 15(12):1311-8. PubMed ID: 25439689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
    Vose JM; Habermann TM; Czuczman MS; Zinzani PL; Reeder CB; Tuscano JM; Lossos IS; Li J; Pietronigro D; Witzig TE
    Br J Haematol; 2013 Sep; 162(5):639-47. PubMed ID: 23834234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).
    Rigacci L; Puccini B; Cortelazzo S; Gaidano G; Piccin A; D'Arco A; Freilone R; Storti S; Orciuolo E; Zinzani PL; Zaja F; Bongarzoni V; Balzarotti M; Rota-Scalabrini D; Patti C; Gobbi M; Carpaneto A; Liberati AM; Bosi A; Iannitto E
    Ann Hematol; 2012 Jul; 91(7):1013-22. PubMed ID: 22349722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.
    Fowler NH; Nastoupil LJ; Hagemeister FB; Neelapu SS; Fayad LE; LeBlanc D; Samaniego F; Cheah CY
    Haematologica; 2015 Nov; 100(11):e454-7. PubMed ID: 26250576
    [No Abstract]   [Full Text] [Related]  

  • 13. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
    Zinzani PL; Pellegrini C; Merla E; Ballerini F; Fabbri A; Guarini A; Pavone V; Quintini G; Puccini B; Vigliotti ML; Stefoni V; Derenzini E; Broccoli A; Gandolfi L; Quirini F; Casadei B; Argnani L; Baccarani M
    Hematol Oncol; 2013 Dec; 31(4):179-82. PubMed ID: 23108928
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab-lenalidomide-dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma.
    Ivanov V; Tabouret E; Chuto G; Chetaille B; Fezoui H; Coso D; Rey J; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2010 Sep; 51(9):1758-60. PubMed ID: 20629527
    [No Abstract]   [Full Text] [Related]  

  • 15. A phase II study to evaluate lenalidomide in combination with metronomic-dose cyclophosphamide in patients with heavily pretreated classical Hodgkin lymphoma.
    Rueda A; García-Sanz R; Pastor M; Salar A; Labrador J; Quero-Blanco C; Casanova M; Provencio M;
    Acta Oncol; 2015 Jun; 54(6):933-8. PubMed ID: 25734915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
    Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
    Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients.
    Zinzani PL; Pellegrini C; Derenzini E; Argnani L; Pileri S
    Hematol Oncol; 2013 Dec; 31(4):223-4. PubMed ID: 23620452
    [No Abstract]   [Full Text] [Related]  

  • 18. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
    J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of lenalinomide combined with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.
    Ivanov V; Coso D; Chetaille B; Esterni B; Olive D; Aurran-Schleinitz T; Schiano JM; Stoppa AM; Broussais-Guillaumot F; Blaise D; Bouabdallah R
    Leuk Lymphoma; 2014 Nov; 55(11):2508-13. PubMed ID: 24506467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed Efficacy After Treatment With Lenalidomide or Thalidomide in Patients With Mucosa-Associated Lymphoid Tissue Lymphoma.
    Kiesewetter B; Troch M; Mayerhoefer ME; Dolak W; Simonitsch-Klupp I; Raderer M
    Oncologist; 2016 Jan; 21(1):72-5. PubMed ID: 26621040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.